Global Methylmalonic Acidemia (MMA) Market Trends and Growth Analysis 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Methylmalonic Acidemia (MMA) Market Over The Five-Year Period 2025–2029?

The methylmalonic acidemia (mma) market size has experienced robust expansion in recent years. It is projected to increase from $9.39 billion in 2024 to $9.94 billion by 2025, achieving a compound annual growth rate (CAGR) of 5.9%. This historical growth can be attributed to several factors, including the rising incidence of metabolic disorders and vitamin deficiencies, elevated healthcare expenditure, a surge in health consciousness, the increasing prevalence of genetic disorders, and growing demand originating from various end-user industries.

The methylmalonic acidemia (mma) market is anticipated to experience substantial growth over the next few years. It is forecast to expand to $12.4 billion by 2029, achieving a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is driven by factors such as the rise in newborn screening programs, enhanced awareness among healthcare professionals, progress in gene therapy, increased investments in rare disease research, and the expanding availability of specialized treatments. Significant trends expected in this period include developments in gene editing technologies, advanced diagnostic techniques for early detection, improvements in enzyme replacement therapies, the embrace of precision medicine approaches, and the implementation of newborn genetic screening programs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

Which Industry Drivers Are Expected To Accelerate The Methylmalonic Acidemia (MMA) Market From 2025 To 2029?

A rising prevalence of metabolic conditions and vitamin deficiencies is projected to stimulate the growth of the methylmalonic acidemia (MMA) market in the future. Metabolic disorders are a range of ailments where the body struggles to process certain nutrients, produce energy, or manage chemical reactions within cells, while vitamin deficiencies occur when the body lacks enough specific vitamins for normal functions. The surge in metabolic disorders and vitamin deficiencies is attributable to unhealthy diets, sedentary lifestyles, and elevated stress levels. Modern diets are frequently high in processed foods, sugars, and unhealthy fats, yet low in essential nutrients, leading to shortages of vitamins and minerals. Metabolic disorders and vitamin deficiencies, particularly vitamin B12 deficiency, impair methylmalonyl-CoA metabolism, resulting in the accumulation of methylmalonic acid and aggravating methylmalonic acidemia (MMA). For instance, in November 2024, the National Institutes of Health, a US-based government agency, reported that the prevalence of vitamin B12 deficiency rose from 4.6% to 5.2%, indicating an additional 507 cases between the third and fourth quarters of 2023. Consequently, the increasing incidence of metabolic disorders and vitamin deficiencies propels the growth of the methylmalonic acidemia (MMA) market.

Which Key Segments Fueling The Methylmalonic Acidemia (MMA) Market?

The methylmalonic acidemia (mma)market covered in this report is segmented –

1) By Indication: Acidosis; Ketosis; Hyperammonemia; Hypoglycaemia; Hyperglycaemia; Neutropenia; Other Indications

2) By Disorder Type: Homocystinuria; Isolated Methylmalonic Acidurias; Combined methylmalonic Aciduria

3) By Distribution Channel: Hospitals; Pharmacies; Clinics; Other Distribution Channels

Subsegments:

1) By Acidosis: Metabolic Acidosis; Lactic Acidosis

2) By Ketosis: Starvation-Induced Ketosis; Diabetic Ketoacidosis

3) By Hyperammonemia: Acute Hyperammonemia; Chronic Hyperammonemia

4) By Hypoglycemia: Fasting Hypoglycemia; Reactive Hypoglycemi

5) By Hyperglycemia: Transient Hyperglycemia; Persistent Hyperglycemia

6) By Neutropenia: Severe Neutropenia; Cyclic Neutropenia

7) By Other Indications: Failure to Thrive; Developmental Delays; Neurological Symptoms; Renal Dysfunction

What Key Innovation Trends Are Fueling Advancements In The Methylmalonic Acidemia (MMA) Market?

Leading firms in the methylmalonic acidemia (MMA) market are prioritizing the creation of novel solutions, including mRNA-based therapies. These aim to enhance treatment outcomes by targeting the fundamental genetic causes of MMA and boosting enzyme function, thus minimizing the buildup of toxic metabolites in affected individuals. Such therapies involve using messenger RNA to direct cells to generate specific proteins, which can aid in preventing or managing conditions like genetic disorders or infections. For example, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, secured U.S. Food and Drug Administration (FDA) approval to incorporate mRNA-3705 into the START pilot program, signifying a notable stride in developing therapies for rare diseases. mRNA-3705 represents an investigational therapy for methylmalonic acidemia (MMA) stemming from MUT deficiency, specifically engineered to restore the absent enzyme via mRNA technology. This treatment employs Moderna’s proprietary lipid nanoparticle (LNP) system, also applied in the mRNA-3927 program for propionic acidemia. The FDA has bestowed mRNA-3705 with orphan drug, fast track, and rare pediatric disease designations, thereby facilitating its expedited development and clinical advancement.

Which Global Market Leaders Are Shaping The Future Of The Methylmalonic Acidemia (MMA) Sector?

Major companies operating in the methylmalonic acidemia (MMA) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

Which Region Is Projected To Lead The Methylmalonic Acidemia (MMA) Market During The Forecast Period?

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Methylmalonic Acidemia (MMA) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp

Browse Through More Reports Similar to the Global Methylmalonic Acidemia (MMA) Market 2025, By The Business Research Company

Cardiometabolic Diseases Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Comprehensive Metabolic Panel Cmp Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/comprehensive-metabolic-panel-cmp-testing-global-market-report

Dimethyl Carbonate Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dimethyl-carbonate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795